

christoph driessen

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2933566/publications.pdf>

Version: 2024-02-01

67
papers

5,101
citations

81743

39
h-index

102304

66
g-index

68
all docs

68
docs citations

68
times ranked

6462
citing authors

#	ARTICLE	IF	CITATIONS
1	Autophagy promotes MHC class II presentation of peptides from intracellular source proteins. Proceedings of the National Academy of Sciences of the United States of America, 2005, 102, 7922-7927.	3.3	573
2	Nonproteasomal Targets of the Proteasome Inhibitors Bortezomib and Carfilzomib: a Link to Clinical Adverse Events. Clinical Cancer Research, 2011, 17, 2734-2743.	3.2	358
3	Personalized therapy in multiple myeloma according to patient age and vulnerability: a report of the European Myeloma Network (EMN). Blood, 2011, 118, 4519-4529.	0.6	309
4	Proteases involved in MHC class II antigen presentation. Immunological Reviews, 1999, 172, 109-120.	2.8	223
5	Role for Cathepsin F in Invariant Chain Processing and Major Histocompatibility Complex Class II Peptide Loading by Macrophages. Journal of Experimental Medicine, 2000, 191, 1177-1186.	4.2	216
6	Cathepsin S Controls the Trafficking and Maturation of Mhc Class II Molecules in Dendritic Cells. Journal of Cell Biology, 1999, 147, 775-790.	2.3	210
7	European Myeloma Network recommendations on the evaluation and treatment of newly diagnosed patients with multiple myeloma. Haematologica, 2014, 99, 232-242.	1.7	185
8	Rituximab in relapsed lymphocyte-predominant Hodgkin lymphoma: long-term results of a phase 2 trial by the German Hodgkin Lymphoma Study Group (GHSG). Blood, 2008, 111, 109-111.	0.6	169
9	Final Results of a Prospective Evaluation of the Predictive Value of Interim Positron Emission Tomography in Patients With Diffuse Large B-Cell Lymphoma Treated With R-CHOP-14 (SAKK 38/07). Journal of Clinical Oncology, 2015, 33, 2523-2529.	0.8	157
10	Treatment of relapsed CD20+ Hodgkin lymphoma with the monoclonal antibody rituximab is effective and well tolerated: results of a phase 2 trial of the German Hodgkin Lymphoma Study Group. Blood, 2003, 101, 420-424.	0.6	145
11	Characterization of the ubiquitin-proteasome system in bortezomib-adapted cells. Leukemia, 2009, 23, 1098-1105.	3.3	125
12	Cancer-Selective Targeting of the NF- κ B Survival Pathway with GADD45 ^Δ /MKK7 Inhibitors. Cancer Cell, 2014, 26, 495-508.	7.7	99
13	Specific role for cathepsin S in the generation of antigenic peptides in vivo. European Journal of Immunology, 2002, 32, 467-476.	1.6	98
14	Cathepsin S and an asparagine-specific endoprotease dominate the proteolytic processing of human myelin basic protein in vitro. European Journal of Immunology, 2001, 31, 3726-3736.	1.6	94
15	Structure-Based Design of β 1i or β 5i Specific Inhibitors of Human Immunoproteasomes. Journal of Medicinal Chemistry, 2014, 57, 6197-6209.	2.9	89
16	A Set of Activity-Based Probes to Visualize Human (Immuno)proteasome Activities. Angewandte Chemie - International Edition, 2016, 55, 4199-4203.	7.2	86
17	Incorporation of Non-natural Amino Acids Improves Cell Permeability and Potency of Specific Inhibitors of Proteasome Trypsin-like Sites. Journal of Medicinal Chemistry, 2013, 56, 1262-1275.	2.9	79
18	Regulation of CD1 Function and NK1.1+ T Cell Selection and Maturation by Cathepsin S. Immunity, 2001, 15, 909-919.	6.6	75

#	ARTICLE	IF	CITATIONS
19	The benefit of using whole-body, low-dose, nonenhanced, multidetector computed tomography for follow-up and therapy response monitoring in patients with multiple myeloma. <i>Cancer</i> , 2007, 109, 1617-1626.	2.0	75
20	Activity patterns of proteasome subunits reflect bortezomib sensitivity of hematologic malignancies and are variable in primary human leukemia cells. <i>Leukemia</i> , 2007, 21, 84-92.	3.3	74
21	A first in human phase I study of the proteasome inhibitor CEP-18770 in patients with advanced solid tumours and multiple myeloma. <i>European Journal of Cancer</i> , 2013, 49, 290-296.	1.3	74
22	Cathepsin G, and Not the Asparagine-Specific Endoprotease, Controls the Processing of Myelin Basic Protein in Lysosomes from Human B Lymphocytes. <i>Journal of Immunology</i> , 2004, 172, 5495-5503.	0.4	73
23	The p41 isoform of invariant chain is a chaperone for cathepsin L. <i>EMBO Journal</i> , 2001, 20, 4055-4064.	3.5	66
24	Syringolin A Selectively Labels the 20S Proteasome in Murine EL4 and Wild Type and Bortezomib-Adapted Leukaemic Cell Lines. <i>ChemBioChem</i> , 2009, 10, 2638-2643.	1.3	65
25	Ritonavir induces endoplasmic reticulum stress and sensitizes sarcoma cells toward bortezomib-induced apoptosis. <i>Molecular Cancer Therapeutics</i> , 2008, 7, 1940-1948.	1.9	64
26	Dual inhibition of proteasomal and lysosomal proteolysis ameliorates autoimmune central nervous system inflammation. <i>European Journal of Immunology</i> , 2008, 38, 2401-2411.	1.6	63
27	Stimulation of Human Peripheral Blood Mononuclear Cells by Zinc and Related Cations. <i>Cytokine</i> , 1996, 8, 767-771.	1.4	57
28	Sensitivity of tumor cells to proteasome inhibitors is associated with expression levels and composition of proteasome subunits. <i>Cancer</i> , 2008, 112, 659-670.	2.0	57
29	Individual cathepsins degrade immune complexes internalized by antigen-presenting cells via Fc γ 3 receptors. <i>European Journal of Immunology</i> , 2001, 31, 1592-1601.	1.6	51
30	Inflammatory stimuli recruit cathepsin activity to late endosomal compartments in human dendritic cells. <i>European Journal of Immunology</i> , 2002, 32, 3348-3357.	1.6	49
31	Differential Processing of Autoantigens in Lysosomes from Human Monocyte-Derived and Peripheral Blood Dendritic Cells. <i>Journal of Immunology</i> , 2005, 175, 5940-5949.	0.4	45
32	Combined Inhibition of p97 and the Proteasome Causes Lethal Disruption of the Secretory Apparatus in Multiple Myeloma Cells. <i>PLoS ONE</i> , 2013, 8, e74415.	1.1	45
33	Antigen processing and presentation in human muscle: cathepsin S is critical for MHC class II expression and upregulated in inflammatory myopathies. <i>Journal of Neuroimmunology</i> , 2003, 138, 132-143.	1.1	44
34	Ritonavir, nelfinavir, saquinavir and lopinavir induce proteotoxic stress in acute myeloid leukemia cells and sensitize them for proteasome inhibitor treatment at low micromolar drug concentrations. <i>Leukemia Research</i> , 2014, 38, 383-392.	0.4	44
35	Treatment with the HIV protease inhibitor nelfinavir triggers the unfolded protein response and may overcome proteasome inhibitor resistance of multiple myeloma in combination with bortezomib: a phase I trial (SAKK 65/08). <i>Haematologica</i> , 2016, 101, 346-355.	1.7	44
36	Nelfinavir augments proteasome inhibition by bortezomib in myeloma cells and overcomes bortezomib and carfilzomib resistance. <i>Blood Cancer Journal</i> , 2013, 3, e103-e103.	2.8	43

#	ARTICLE	IF	CITATIONS
37	Early endosomal maturation of MHC class II molecules independently of cysteine proteases and H-2DM. <i>EMBO Journal</i> , 2000, 19, 882-891.	3.5	41
38	Hyperattenuating bone marrow abnormalities in myeloma patients using whole-body non-enhanced low-dose MDCT: correlation with haematological parameters. <i>British Journal of Radiology</i> , 2008, 81, 386-396.	1.0	39
39	The novel $\hat{A}2$ -selective proteasome inhibitor LU-102 synergizes with bortezomib and carfilzomib to overcome proteasome inhibitor resistance of myeloma cells. <i>Haematologica</i> , 2015, 100, 1350-1360.	1.7	39
40	Divergent Effects of Zinc on Different Bacterial Pathogenic Agents. <i>Journal of Infectious Diseases</i> , 1995, 171, 486-489.	1.9	38
41	A new approach for distinguishing cathepsin \hat{e} and D activity in antigen-processing organelles. <i>FEBS Journal</i> , 2007, 274, 3138-3149.	2.2	35
42	Receptor-mediated Targeting of Cathepsins in Professional Antigen Presenting Cells. <i>Angewandte Chemie - International Edition</i> , 2009, 48, 1629-1632.	7.2	35
43	Human plasma thrombopoietin levels are regulated by binding to platelet thrombopoietin receptors in vivo. <i>Transfusion</i> , 2002, 42, 321-327.	0.8	32
44	A novel cell penetrating aspartic protease inhibitor blocks processing and presentation of tetanus toxoid more efficiently than pepstatin A. <i>Biochemical and Biophysical Research Communications</i> , 2007, 364, 243-249.	1.0	32
45	Cathepsin S dominates autoantigen processing in human thymic dendritic cells. <i>Journal of Autoimmunity</i> , 2012, 38, 332-343.	3.0	32
46	Activity and subcellular distribution of cathepsins in primary human monocytes. <i>Journal of Leukocyte Biology</i> , 2003, 73, 235-242.	1.5	31
47	Development of an isotope-coded activity-based probe for the quantitative profiling of cysteine proteases. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2004, 14, 3131-3134.	1.0	31
48	Human B lymphoblastoid cells contain distinct patterns of cathepsin activity in endocytic compartments and regulate MHC class II transport in a cathepsin S-independent manner. <i>Journal of Leukocyte Biology</i> , 2004, 75, 844-855.	1.5	30
49	Cathepsin G is differentially expressed in primary human antigen-presenting cells. <i>Cellular Immunology</i> , 2009, 255, 41-45.	1.4	28
50	An inhibitor of proteasome $\hat{2}$ sites sensitizes myeloma cells to immunoproteasome inhibitors. <i>Blood Advances</i> , 2018, 2, 2443-2451.	2.5	27
51	Promising activity of nelfinavir-bortezomib-dexamethasone in proteasome inhibitor-refractory multiple myeloma. <i>Blood</i> , 2018, 132, 2097-2100.	0.6	27
52	Direct and two-step bioorthogonal probes for Bruton's tyrosine kinase based on ibrutinib: a comparative study. <i>Organic and Biomolecular Chemistry</i> , 2015, 13, 5147-5157.	1.5	26
53	Consolidation and Maintenance in Newly Diagnosed Multiple Myeloma. <i>Journal of Clinical Oncology</i> , 2021, 39, 3613-3622.	0.8	25
54	Endocytosis targets exogenous material selectively to cathepsin S in live human dendritic cells, while cell-penetrating peptides mediate nonselective transport to cysteine cathepsins. <i>Journal of Leukocyte Biology</i> , 2007, 81, 990-1001.	1.5	24

#	ARTICLE	IF	CITATIONS
55	Specificity of human cathepsin S determined by processing of peptide substrates and MHC class II-associated invariant chain. <i>Biological Chemistry</i> , 2006, 387, 1503-11.	1.2	23
56	Improved survival of older patients with multiple myeloma in the era of novel agents. <i>Hematological Oncology</i> , 2016, 34, 217-223.	0.8	23
57	Intravascular Lymphoma Mimicking Cerebral Stroke: Report of Two Cases. <i>Case Reports in Neurology</i> , 2011, 3, 278-283.	0.3	21
58	Modulation of the Endosomal and Lysosomal Distribution of Cathepsins B, L and S in Human Monocytes/Macrophages. <i>Biological Chemistry</i> , 2002, 383, 1277-83.	1.2	20
59	Characterization of Legumain. <i>Biological Chemistry</i> , 2002, 383, 1813-1816.	1.2	20
60	Interferon- γ regulates cathepsin G activity in microglia-derived lysosomes and controls the proteolytic processing of myelin basic protein in vitro. <i>Immunology</i> , 2007, 121, 82-93.	2.0	18
61	Probing the potential of platinum(II) complexes for the inhibition of thiol-dependent enzymatic activity. <i>Journal of Inorganic Biochemistry</i> , 2005, 99, 1384-1389.	1.5	16
62	Biotinylated fluorescent peptide substrates for the sensitive and specific determination of cathepsin D activity. <i>Journal of Peptide Science</i> , 2005, 11, 166-174.	0.8	16
63	Human cytomegalovirus infection interferes with major histocompatibility complex type II maturation and endocytic proteases in dendritic cells at multiple levels. <i>Journal of General Virology</i> , 2008, 89, 2427-2436.	1.3	16
64	European Myeloma Network: the 3rd Trialist Forum Consensus Statement from the European experts meeting on multiple myeloma. <i>Leukemia and Lymphoma</i> , 2010, 51, 2006-2011.	0.6	14
65	The novel β 2-selective proteasome inhibitor LU-102 decreases phosphorylation of I kappa B and induces highly synergistic cytotoxicity in combination with ibrutinib in multiple myeloma cells. <i>Cancer Chemotherapy and Pharmacology</i> , 2015, 76, 383-396.	1.1	13
66	Imatinib mesylate and nilotinib affect MHC-class I presentation by modulating the proteasomal processing of antigenic peptides. <i>Cancer Immunology, Immunotherapy</i> , 2013, 62, 715-726.	2.0	6
67	Complete hematological and major molecular response through treatment with low-dose Interferon alpha 2a in high-risk polycythemia vera patient: a case report. <i>Clinical Case Reports (discontinued)</i> , 2021, 9, e04903.	0.2	0